GRI Bio reports FY2024 net loss of $8.2M; cash runway into Q2 2025

GRI Bio, Inc.

Net loss of $8.2M for FY2024; R&D spend increased 19% to $3.8M; G&A fell 45% to $4.5M.
Cash and equivalents of $5.0M at Dec 31, 2024; runway only into Q2 2025 (through interim data).
Phase 2a interim data for GRI-0621 in IPF expected Q2 2025; topline results Q3 2025.
European patent granted for GRI-0803 and library of 500+ proprietary NKT cell modulators.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.